TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors
NCT ID: NCT04976660
Last Updated: 2025-03-18
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
WITHDRAWN
Clinical Phase
PHASE1/PHASE2
Study Classification
INTERVENTIONAL
Study Start Date
2022-12-15
Study Completion Date
2023-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to evaluate the safety and tolerability of orally administered TT-4 in subjects with advanced selected solid tumors. The dose escalation portion of the study will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of TT-4.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
NCT04969315
Renal Cell Cancer
Castrate Resistant Prostate Cancer
Non Small Cell Lung Cancer
+4 more
RECRUITING
PHASE1/PHASE2
First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors
NCT04746612
Advanced Solid Tumors
TERMINATED
PHASE1
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
NCT04780217
Solid Tumor
Hepatocellular Carcinoma
Colorectal Cancer
+3 more
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
NCT05121948
Squamous Cell Carcinoma of Head and Neck
Colo-rectal Cancer
Non Small Cell Lung Cancer
+3 more
TERMINATED
PHASE1
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
NCT06403436
Advanced Solid Tumor
Adult Solid Tumor
Adult Disease
+5 more
RECRUITING
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Multicenter, open-label dose-escalation Phase I/II clinical study, designed to evaluate the safety, tolerability, PK, PD, anti-tumor activity, and efficacy of TT-4 in subjects diagnosed with Colorectal Cancer (CRC), Gastric cancer (GC), Hepatocellular Carcinoma (HCC) and locally advanced, unresectable, or metastatic Pancreatic Cancer (PANC); who have failed or are not eligible for standard of care treatment.
The study will be conducted in two phases. Dose escalation (Phase 1) will be to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D), safety and tolerability of TT-4 in subjects with advanced subjects diagnosed with Colorectal Cancer (CRC), Gastric cancer (GC), Hepatocellular Carcinoma (HCC) and locally advanced, unresectable, or metastatic Pancreatic Cancer (PANC); who have failed or are not eligible for standard of care treatment. Dose expansion (Phase 2) will be to further explore the safety and tolerability of the MTD and/or RP2D, PK, PD, antitumor activity, and efficacy of TT-4.
The study will be conducted in two phases. Dose escalation (Phase 1) will be to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D), safety and tolerability of TT-4 in subjects with advanced subjects diagnosed with Colorectal Cancer (CRC), Gastric cancer (GC), Hepatocellular Carcinoma (HCC) and locally advanced, unresectable, or metastatic Pancreatic Cancer (PANC); who have failed or are not eligible for standard of care treatment. Dose expansion (Phase 2) will be to further explore the safety and tolerability of the MTD and/or RP2D, PK, PD, antitumor activity, and efficacy of TT-4.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Colorectal Cancer
Gastric Cancer
Hepatocellular Carcinoma
Pancreatic Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SEQUENTIAL
3+3 Design
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Multiple Ascending Dose
3+3 Dose escalation until MTD and/or R2PD of TT-4 is determined
Group Type
EXPERIMENTAL
TT-4
Intervention Type
DRUG
TT-4 orally administered QD starting at 200 mg and will be increased to 800 mg (dosing may be increased to BID, if appropriate based on emerging safety, PK or PD data).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TT-4
TT-4 orally administered QD starting at 200 mg and will be increased to 800 mg (dosing may be increased to BID, if appropriate based on emerging safety, PK or PD data).
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
To eligible for inclusion in the dose escalation cohort or expansion cohort 1 in this study, subjects must meet all of the following criteria:
1. Subjects must be ≥18 years of age.
2. Subjects or their legal representative must be able to provide written informed consent to participate in the trial prior to the performance of any study-specific procedures.
3. Diagnosis of histologically or cytologically confirmed advanced selected solid tumors
* Cohort A dose escalation: Colorectal Cancer, Gastric cancer, Hepatocellular Carcinoma and locally advanced, unresectable, or metastatic Pancreatic Cancer, who have failed or are not eligible for standard of care treatment.
* Cohort B: Advanced colorectal cancer (CRC), who have failed or not eligible for standard of care
* Cohort C: Advanced Gastric cancer (GC), who have failed or not eligible for standard of care
* Cohort D: Advanced Hepatocellular Carcinoma (HCC), who have failed or not eligible for standard of care
* Cohort E: Locally advanced, unresectable, or metastatic Pancreatic Cancer (PANC), who have failed or not eligible for standard of care
4. ECOG performance status (PS) score 0-1
5. Have measurable disease per RECIST 1.1 or (for subjects in the expansion cohorts) iRECIST as assessed by the local site investigator/radiology. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
6. Subjects must have locally advanced, recurrent or metastatic neoplastic disease that is not curable by currently available therapies.
7. Failure to respond to standard therapy, or for whom no appropriate therapies are available (based on the judgment of the Investigator)
8. Life expectancy of ≥ 3 months
9. Subjects must have adequate hematologic function based on the following:
* Absolute neutrophil count ≥ 1.5 x 109/L
* Platelet count ≥ 100 x 109/L
* Hemoglobin ≥ 9.0 g/dL
10. Subjects must have adequate hepatic function based on the following:
* Total bilirubin \<1.5 × upper limit of normal (ULN) Patients with a known history of Gilbert's syndrome (≤ 3.0 × ULN) and/or isolated elevations of indirect bilirubin are eligible for study participation
* Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤2.5 x ULN (≤5 × ULN for subjects with known hepatic metastases)
11. Subjects must have adequate renal function based on the following:
\- Serum creatinine ≤1.5 × ULN
12. For women of childbearing potential (WCBP): negative serum β human chorionic gonadotropin (βhCG) pregnancy test within 1 week before first treatment (WCBP defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally post-menopausal for at least 12 consecutive months for women \> 55 years of age)
13. Human immunodeficiency virus (HIV) infected subjects must be on antiretroviral therapy (ART) and have a well-controlled HIV infection/disease defined as:
1. Subjects on ART must have a CD4+ T cell count \>350 cells/mm3 at time of screening
2. Subjects on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 copies/mL or the lower limit of qualification (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks prior to screening
3. Subjects on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks prior to study entry (Day 1).
14. For women of childbearing potential (WCBP): negative urine pregnancy test (UPT) within 1 week before first treatment (WCBP defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally post-menopausal for at least 12 consecutive months for women \> 55 years of age). WCBP should be placed on effective birth control directly after testing negative for pregnancy; if not, then WCBP should have a UPT on Day 1 of every cycle, prior to drug administration. Any positive or indeterminant UPT result must be confirmed by Serum.
15. Female subjects of childbearing potential must use a highly effective mode of contraception or abstain from heterosexual activity for the duration of the trial and for 120 days following the last dose of study medication. A female is NOT of childbearing potential if she has undergone bilateral salpingoophorectomy or is menopausal, defined as an absence of menses for 12 consecutive months. Male subjects must agree to use highly effective contraception.
16. Ability to adhere to the study visit schedule and all protocol requirements
1. Subjects must be ≥18 years of age.
2. Subjects or their legal representative must be able to provide written informed consent to participate in the trial prior to the performance of any study-specific procedures.
3. Diagnosis of histologically or cytologically confirmed advanced selected solid tumors
* Cohort A dose escalation: Colorectal Cancer, Gastric cancer, Hepatocellular Carcinoma and locally advanced, unresectable, or metastatic Pancreatic Cancer, who have failed or are not eligible for standard of care treatment.
* Cohort B: Advanced colorectal cancer (CRC), who have failed or not eligible for standard of care
* Cohort C: Advanced Gastric cancer (GC), who have failed or not eligible for standard of care
* Cohort D: Advanced Hepatocellular Carcinoma (HCC), who have failed or not eligible for standard of care
* Cohort E: Locally advanced, unresectable, or metastatic Pancreatic Cancer (PANC), who have failed or not eligible for standard of care
4. ECOG performance status (PS) score 0-1
5. Have measurable disease per RECIST 1.1 or (for subjects in the expansion cohorts) iRECIST as assessed by the local site investigator/radiology. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
6. Subjects must have locally advanced, recurrent or metastatic neoplastic disease that is not curable by currently available therapies.
7. Failure to respond to standard therapy, or for whom no appropriate therapies are available (based on the judgment of the Investigator)
8. Life expectancy of ≥ 3 months
9. Subjects must have adequate hematologic function based on the following:
* Absolute neutrophil count ≥ 1.5 x 109/L
* Platelet count ≥ 100 x 109/L
* Hemoglobin ≥ 9.0 g/dL
10. Subjects must have adequate hepatic function based on the following:
* Total bilirubin \<1.5 × upper limit of normal (ULN) Patients with a known history of Gilbert's syndrome (≤ 3.0 × ULN) and/or isolated elevations of indirect bilirubin are eligible for study participation
* Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤2.5 x ULN (≤5 × ULN for subjects with known hepatic metastases)
11. Subjects must have adequate renal function based on the following:
\- Serum creatinine ≤1.5 × ULN
12. For women of childbearing potential (WCBP): negative serum β human chorionic gonadotropin (βhCG) pregnancy test within 1 week before first treatment (WCBP defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally post-menopausal for at least 12 consecutive months for women \> 55 years of age)
13. Human immunodeficiency virus (HIV) infected subjects must be on antiretroviral therapy (ART) and have a well-controlled HIV infection/disease defined as:
1. Subjects on ART must have a CD4+ T cell count \>350 cells/mm3 at time of screening
2. Subjects on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 copies/mL or the lower limit of qualification (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks prior to screening
3. Subjects on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks prior to study entry (Day 1).
14. For women of childbearing potential (WCBP): negative urine pregnancy test (UPT) within 1 week before first treatment (WCBP defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally post-menopausal for at least 12 consecutive months for women \> 55 years of age). WCBP should be placed on effective birth control directly after testing negative for pregnancy; if not, then WCBP should have a UPT on Day 1 of every cycle, prior to drug administration. Any positive or indeterminant UPT result must be confirmed by Serum.
15. Female subjects of childbearing potential must use a highly effective mode of contraception or abstain from heterosexual activity for the duration of the trial and for 120 days following the last dose of study medication. A female is NOT of childbearing potential if she has undergone bilateral salpingoophorectomy or is menopausal, defined as an absence of menses for 12 consecutive months. Male subjects must agree to use highly effective contraception.
16. Ability to adhere to the study visit schedule and all protocol requirements
Exclusion Criteria
Subjects are to be excluded from the study if they meet any of the following criteria:
1. Major surgery within 4 weeks prior to Screening
2. Anti-cancer therapy, such as chemotherapy, immunotherapy, hormonal therapy, targeted therapy, or investigational agents within five half-lives or four weeks, whichever is shorter, prior to administration of the first dose of study treatment.
3. Subjects with active central nervous system (CNS) metastases; however, subjects who have undergone radiation and/or surgery for the treatment of CNS metastases, who are neurologically stable, and who are no longer taking pharmacologic doses of corticosteroids are eligible; subjects with leptomeningeal metastases are not eligible.
4. Has received prior radiotherapy within 2 weeks of start of study treatment. Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
5. Primary CNS malignancy
6. HIV-infected subjects with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.
7. Subjects who are hepatitis B surface antigen positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to enrollment.
Note: Subjects should remain on antiviral therapy throughout study intervention and follow local guidelines for HBV antiviral therapy post completion of study intervention.
Hepatitis B screening tests are not required unless:
* Known history of HBV infection
* As mandated by local health authority.
8. Subjects with a history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening. Note: Subjects must have completed curative antiviral therapy at least 4 weeks prior to enrollment.
Hepatitis C screening tests are not required unless:
* Known history of HCV infection
* As mandated by local health authority.
9. Subjects who require immunosuppressive therapy including, but not limited to, treatment with corticosteroids in pharmacologic doses (equivalent to ≥10 mg prednisone daily), cyclosporine, mycophenolate, azathioprine, methotrexate, adalimumab, infliximab, vedolizumab, tofacitinib, dupilumab, rituximab, etc. or systemic steroids (except for steroid use as cortisol replacement therapy in documented adrenal insufficiency)
10. Ongoing systemic bacterial, fungal, or viral infections at Screening
11. Administration of a live vaccine within 30 days of first dose of study drug
12. Baseline QT interval corrected with Fridericia's method (QTcF) \> 480 ms (average of triplicate readings)
a. NOTE: Criterion does not apply to subjects with a right or left bundle branch block.
13. Subjects with a history of Torsade de Pointes or taking QT-prolonging drugs
14. Prior surgery or gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy)
15. Female subjects who are pregnant or breastfeeding
16. Concurrent active malignancy other than non-melanoma skin cancer, carcinoma in situ of the cervix, or prostate intraepithelial neoplasia
17. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
18. History of peptic ulcer and/or gastrointestinal bleed within the past 6 months prior to Screening
19. History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months prior to Screening
20. Unstable or severe uncontrolled medical condition (eg, unstable cardiac function, unstable pulmonary condition including pneumonitis and/or interstitial lung disease, uncontrolled diabetes) or any important medical illness or abnormal laboratory finding that would, in the Investigator's judgment, increase the risk to the subject associated with his or her participation in the study
1. Major surgery within 4 weeks prior to Screening
2. Anti-cancer therapy, such as chemotherapy, immunotherapy, hormonal therapy, targeted therapy, or investigational agents within five half-lives or four weeks, whichever is shorter, prior to administration of the first dose of study treatment.
3. Subjects with active central nervous system (CNS) metastases; however, subjects who have undergone radiation and/or surgery for the treatment of CNS metastases, who are neurologically stable, and who are no longer taking pharmacologic doses of corticosteroids are eligible; subjects with leptomeningeal metastases are not eligible.
4. Has received prior radiotherapy within 2 weeks of start of study treatment. Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
5. Primary CNS malignancy
6. HIV-infected subjects with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.
7. Subjects who are hepatitis B surface antigen positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to enrollment.
Note: Subjects should remain on antiviral therapy throughout study intervention and follow local guidelines for HBV antiviral therapy post completion of study intervention.
Hepatitis B screening tests are not required unless:
* Known history of HBV infection
* As mandated by local health authority.
8. Subjects with a history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening. Note: Subjects must have completed curative antiviral therapy at least 4 weeks prior to enrollment.
Hepatitis C screening tests are not required unless:
* Known history of HCV infection
* As mandated by local health authority.
9. Subjects who require immunosuppressive therapy including, but not limited to, treatment with corticosteroids in pharmacologic doses (equivalent to ≥10 mg prednisone daily), cyclosporine, mycophenolate, azathioprine, methotrexate, adalimumab, infliximab, vedolizumab, tofacitinib, dupilumab, rituximab, etc. or systemic steroids (except for steroid use as cortisol replacement therapy in documented adrenal insufficiency)
10. Ongoing systemic bacterial, fungal, or viral infections at Screening
11. Administration of a live vaccine within 30 days of first dose of study drug
12. Baseline QT interval corrected with Fridericia's method (QTcF) \> 480 ms (average of triplicate readings)
a. NOTE: Criterion does not apply to subjects with a right or left bundle branch block.
13. Subjects with a history of Torsade de Pointes or taking QT-prolonging drugs
14. Prior surgery or gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy)
15. Female subjects who are pregnant or breastfeeding
16. Concurrent active malignancy other than non-melanoma skin cancer, carcinoma in situ of the cervix, or prostate intraepithelial neoplasia
17. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
18. History of peptic ulcer and/or gastrointestinal bleed within the past 6 months prior to Screening
19. History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months prior to Screening
20. Unstable or severe uncontrolled medical condition (eg, unstable cardiac function, unstable pulmonary condition including pneumonitis and/or interstitial lung disease, uncontrolled diabetes) or any important medical illness or abnormal laboratory finding that would, in the Investigator's judgment, increase the risk to the subject associated with his or her participation in the study
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tarus Therapeutics, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
References
Explore related publications, articles, or registry entries linked to this study.
Antonioli L, Blandizzi C, Pacher P, Hasko G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer. 2013 Dec;13(12):842-57. doi: 10.1038/nrc3613. Epub 2013 Nov 14.
Reference Type
BACKGROUND
Cekic C, Sag D, Li Y, Theodorescu D, Strieter RM, Linden J. Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol. 2012 Jan 1;188(1):198-205. doi: 10.4049/jimmunol.1101845. Epub 2011 Nov 23.
Reference Type
BACKGROUND
Aherne CM, Kewley EM, Eltzschig HK. The resurgence of A2B adenosine receptor signaling. Biochim Biophys Acta. 2011 May;1808(5):1329-39. doi: 10.1016/j.bbamem.2010.05.016. Epub 2010 May 28.
Reference Type
BACKGROUND
Allard B, Allard D, Buisseret L, Stagg J. The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol. 2020 Oct;17(10):611-629. doi: 10.1038/s41571-020-0382-2. Epub 2020 Jun 8.
Reference Type
BACKGROUND
Zhou Y, Chu X, Deng F, Tong L, Tong G, Yi Y, Liu J, Tang J, Tang Y, Xia Y, Dai Y. The adenosine A2b receptor promotes tumor progression of bladder urothelial carcinoma by enhancing MAPK signaling pathway. Oncotarget. 2017 Jul 25;8(30):48755-48768. doi: 10.18632/oncotarget.17835.
Reference Type
BACKGROUND
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litiere S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2.
Reference Type
BACKGROUND
Horigome E, Fujieda M, Handa T, Katayama A, Ito M, Ichihara A, Tanaka D, Gombodorj N, Yoshiyama S, Yamane A, Yamada K, Horiguchi J, Shinozuka K, Oyama T, Nishiyama M, Rokudai S. Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling. Oncotarget. 2018 Oct 2;9(77):34554-34566. doi: 10.18632/oncotarget.26177. eCollection 2018 Oct 2.
Reference Type
BACKGROUND
Vecchio EA, Tan CY, Gregory KJ, Christopoulos A, White PJ, May LT. Ligand-Independent Adenosine A2B Receptor Constitutive Activity as a Promoter of Prostate Cancer Cell Proliferation. J Pharmacol Exp Ther. 2016 Apr;357(1):36-44. doi: 10.1124/jpet.115.230003. Epub 2016 Jan 20.
Reference Type
BACKGROUND
Lan J, Lu H, Samanta D, Salman S, Lu Y, Semenza GL. Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment. Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):E9640-E9648. doi: 10.1073/pnas.1809695115. Epub 2018 Sep 21.
Reference Type
BACKGROUND
Ma DF, Kondo T, Nakazawa T, Niu DF, Mochizuki K, Kawasaki T, Yamane T, Katoh R. Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells. Hum Pathol. 2010 Nov;41(11):1550-7. doi: 10.1016/j.humpath.2010.04.008.
Reference Type
BACKGROUND
Ryzhov S, Novitskiy SV, Zaynagetdinov R, Goldstein AE, Carbone DP, Biaggioni I, Dikov MM, Feoktistov I. Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia. 2008 Sep;10(9):987-95. doi: 10.1593/neo.08478.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TT-4-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer
NCT05076552
ACTIVE_NOT_RECRUITING
PHASE1
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
NCT04344795
COMPLETED
PHASE1
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
NCT06005740
RECRUITING
PHASE1
TH1902 in Patients With Advanced Solid Tumors
NCT04706962
ACTIVE_NOT_RECRUITING
PHASE1
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
NCT04198818
TERMINATED
PHASE1/PHASE2
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
A Study of CS3002 in Subjects With Advanced Solid Tumors
NCT04162301
TERMINATED
PHASE1
First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
NCT01529307
TERMINATED
PHASE1
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
NCT02078752
TERMINATED
PHASE1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
NCT04969835
RECRUITING
PHASE1
A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies
NCT01204073
COMPLETED
PHASE1
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
NCT02503423
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
NCT06884618
RECRUITING
PHASE1
Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors
NCT03604783
TERMINATED
PHASE1
A Phase 1 Study of NM6603 in Advanced Solid Tumors
NCT06046066
RECRUITING
PHASE1
Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors
NCT05156203
RECRUITING
PHASE1
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT06657222
RECRUITING
PHASE1/PHASE2
A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors
NCT06669975
RECRUITING
PHASE1/PHASE2
A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors
NCT00400023
COMPLETED
PHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
NCT06488716
TERMINATED
PHASE1
A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors
NCT06598007
RECRUITING
PHASE1/PHASE2
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
NCT05269316
RECRUITING
PHASE1/PHASE2
Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors
NCT06652529
NOT_YET_RECRUITING
PHASE1
A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors
NCT07165067
RECRUITING
PHASE1
Phase 1 Study of Oral TP-1454
NCT04328740
COMPLETED
PHASE1